智雲健康(09955.HK)血糖控制藥「和唐淨」進入上市銷售階段
智雲健康(09955.HK)公布,集團享有銷售權益的自營產品「和唐淨」達格列淨片上市會於昨日(9日)舉行,標誌著該產品自2023年12月13日正式獲得國家藥品監督管理局頒發的藥品註冊證(國藥准字H20234636)後進入上市銷售階段。
達格列淨片是鈉-葡萄糖協同轉運蛋白2(SGLT-2)抑制劑類唯一基本藥物,作為SGLT-2抑制劑,達格列淨片是二型糖尿病成人患者改善血糖控制的一線用藥。多項研究表明,達格列淨片可綜合管理心腎疾病的多重危險因素,在降低糖化血紅蛋白、減輕體重、降低尿酸、降低尿白蛋白與肌酐比和降低收縮壓等方面均有一定效果。
公司認為,「和唐淨」達格列淨片的上市發布是公司從患者到工業模式的有力印證,預計將對公司的財務表現和長遠發展有著積極的推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.